Retail News Breaks Archives
NACDS submits comments as Senate reviews PDUFA
July 29th, 2011
ALEXANDRIA, Va. – The National Association of Chain Drug Stores has provided input to a Senate committee as it reviews the Prescription Drug User Fee Act (PDUFA).
NACDS said Thursday that it submitted comments to the Senate Health, Education, Labor and Pensions Committee (HELP) that highlight community pharmacy's efforts in promoting drug safety and the proper use of prescription drugs to help improve patient health. The association's statement was provided for a committee hearing titled, "FDA User Fees: Advancing Public Health."
In its comments, NACDS outlined its efforts in improving patient health via medication therapy management (MTM) services; targeting illicit drug sellers, especially illegitimate websites selling medications; improving the communication of patient medication information; and working with law enforcement to return and dispose of unwanted prescription drugs.
"NACDS and the chain pharmacy industry support the goals of providing consumers with safe medications and working to prevent illegitimate Internet drug sellers from targeting U.S. consumers with unsafe medications. We also support providing patients with a useful and understandable drug information document — the 'one document solution' — and providing patients with a safe and legal means for disposal of their unused medications. We believe that these are important issues surrounding the use of prescription drugs," the association stated in its comments.
"In addition, we are devoted to important initiatives to improve patients' adherence to their prescribed medications. Chain pharmacies and their pharmacists work with their patients daily to provide them with information and counseling on the proper use of their prescription medications and the importance of adhering to their prescription drug treatment," NACDS added.
PDUFA, enacted in 1992 and renewed several times since then, authorizes the Food and Drug Administration to collect fees from companies that make certain prescription drugs and biological products, including application fees, establishment fees and product fees. According to the FDA, user fees have played a key role in expediting the drug approval process since the enactment of PDUFA.